Literature DB >> 24585100

Role of BAFF in pediatric patients with allergic rhinitis during sublingual immunotherapy.

Renzhong Luo1, Wenlong Liu, Jie Wang, Yanqiu Chen, Changzhi Sun, Lifeng Zhou, Yan Li, Li Deng.   

Abstract

UNLABELLED: Sublingual immunotherapy (SLIT) is the only therapeutic option for allergic rhinitis (AR) that modifies the immunological process to an allergen, rather than treating symptoms simply. However, its regulatory mechanisms are largely unknown. B-cell-activating factor of the TNF family (BAFF) plays very important roles in the development, differentiation, and proliferation of B cells and T cells. The aim of this study was to identify the role of BAFF during SLIT in pediatric patients with AR. Seventy-two house dust mite (HDM)-sensitized pediatric patients with AR were enrolled in this study. Thirty-six pediatric patients received HDM allergen extract for SLIT and 36 pediatric patients received placebo. Serum and nasal aspirate of different time points during treatment was collected and used for enzyme-linked immunosorbent assay (ELISA) of BAFF and related cytokines, respectively. Peripheral blood mononuclear cells were collected and stimulated by HDM allergen with or without rhBAFF after 12 months of treatment. Our results showed that the expression of BAFF protein decreased during the SLIT treatment compared with that in the placebo group after 6 months of therapy, and this trend lasted for 12 months. The decreased BAFF expression was positively related to Th2 cytokines and increased IL-10 expression. BAFF was also related to local production of IgA. In vitro experiments showed that BAFF can promote Th2 cytokines and inhibit IL-10 expression by PBMCs.
CONCLUSION: During SLIT, BAFF expression was decreased and related to low Th2 cytokine expression and enhanced IL-10 expression. Besides, BAFF may contribute to local production of IgA. Our results suggested that BAFF may be an important biomarker during SLIT. Authors' summary. Sublingual immunotherapy (SLIT) is the only therapeutic option for allergic rhinitis (AR) that modifies the immunological process to an allergen, rather than simply treating symptoms. However, its regulatory mechanisms are largely unknown. B-cell-activating factor of the TNF family (BAFF) plays very important roles in the development, differentiation, and proliferation of B cells and T cells. Our results showed that during SLIT, BAFF expression was decreased and related to low Th2 cytokine expression and enhanced IL-10 expression. Besides, BAFF may contribute to local production of IgA. Our results suggested that BAFF may be an important biomarker during SLIT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24585100     DOI: 10.1007/s00431-014-2287-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  27 in total

1.  Standards for practical allergen-specific immunotherapy.

Authors:  E Alvarez-Cuesta; J Bousquet; G W Canonica; S R Durham; H-J Malling; E Valovirta
Journal:  Allergy       Date:  2006       Impact factor: 13.146

Review 2.  B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling.

Authors:  Fabienne Mackay; Pablo A Silveira; Robert Brink
Journal:  Curr Opin Immunol       Date:  2007-04-12       Impact factor: 7.486

3.  B cell-activating factor is a novel diagnosis parameter for asthma.

Authors:  Jong-Soon Kang; Yeo-Dae Yoon; Joong-Hyun Ahn; Seok-Chan Kim; Kwan-Hyoung Kim; Hwan-Mook Kim; Eun-Yi Moon
Journal:  Int Arch Allergy Immunol       Date:  2006-08-04       Impact factor: 2.749

4.  Sublingual immunotherapy with house dust extract for house dust-mite allergic rhinitis in children.

Authors:  Syuji Yonekura; Yoshitaka Okamoto; Daiju Sakurai; Shigetoshi Horiguchi; Toyoyuki Hanazawa; Atsuko Nakano; Fumiyo Kudou; Yuji Nakamaru; Kohei Honda; Akira Hoshioka; Naoki Shimojo; Yoichi Kohno
Journal:  Allergol Int       Date:  2010-09-25       Impact factor: 5.836

5.  Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood.

Authors:  Bengt Björkstén; Tadd Clayton; Philippa Ellwood; Alistair Stewart; David Strachan
Journal:  Pediatr Allergy Immunol       Date:  2007-07-25       Impact factor: 6.377

6.  Efficacy and safety of sublingual immunotherapy in Asian children.

Authors:  Il-Ho Park; Sung-Moon Hong; Heung-Man Lee
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2012-09-05       Impact factor: 1.675

7.  Increased B cell-activating factor (BAFF) level in the sputum of children with asthma.

Authors:  Hye Mi Jee; Bong Seok Choi; Kyung Won Kim; Myung Hyun Sohn; Man Yong Han; Kyu-Earn Kim
Journal:  Korean J Pediatr       Date:  2010-08-31

8.  BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.

Authors:  P Schneider; F MacKay; V Steiner; K Hofmann; J L Bodmer; N Holler; C Ambrose; P Lawton; S Bixler; H Acha-Orbea; D Valmori; P Romero; C Werner-Favre; R H Zubler; J L Browning; J Tschopp
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

9.  APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth.

Authors:  M Hahne; T Kataoka; M Schröter; K Hofmann; M Irmler; J L Bodmer; P Schneider; T Bornand; N Holler; L E French; B Sordat; D Rimoldi; J Tschopp
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

10.  Prevention of arthritis by interleukin 10-producing B cells.

Authors:  Claudia Mauri; David Gray; Naseem Mushtaq; Marco Londei
Journal:  J Exp Med       Date:  2003-02-17       Impact factor: 14.307

View more
  2 in total

1.  Sublingual Immunotherapy Decreases Expression of Interleukin-33 in Children with Allergic Rhinitis.

Authors:  Yuanming Wang; Chuling Li; Yaxiong Xu; Deyu Xu; Gang Yang; Fang Liao; Xianglin Luo
Journal:  Indian J Pediatr       Date:  2018-05-23       Impact factor: 1.967

Review 2.  New therapeutic perspectives for IgA nephropathy in children.

Authors:  Alexandra Cambier; Patrick J Gleeson; Héloise Flament; Marie-Bénédicte Le Stang; Renato C Monteiro
Journal:  Pediatr Nephrol       Date:  2020-02-10       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.